Try our Advanced Search for more refined results

Medina v. Clovis Oncology, Inc. et al

  1. June 23, 2017

    Clovis Reaches $142M Deal To Resolve Stock Drop Suit

    Clovis Oncology Inc. has agreed to pay $142 million in cash and stock to settle a proposed class action that claimed the company inflated its stock price by misleading investors about the efficacy of a cancer drug, shareholders told a Colorado federal court Thursday.

  2. March 20, 2017

    Clovis Oncology Stock-Drop Claims Still Fall Short, Court Told

    Three underwriters accused of helping Clovis Oncology Inc. defraud investors in a stock offering asked a Colorado federal court Friday to dismiss claims against them, saying changes that were supposed to clarify the allegation were "slight" and did not clear the legal hurdle.

  3. February 09, 2017

    Clovis Cancer-Drug Class Action Survives Dismissal Bid

    A Colorado federal judge on Thursday refused to dismiss a shareholder putative class action against Clovis Oncology Inc. that claims the drugmaker publicly touted a lung cancer drug it was developing while feeding bad trial data to the U.S. Food and Drug Administration.

  4. November 20, 2015

    Cancer-Drug Maker's FDA Data Incited Stock Drop, Suits Say

    Clovis Oncology Inc.'s stock price plunged after the drugmaker revealed it gave the U.S. Food and Drug Administration immature clinical trial data when seeking approval for lung cancer drug rociletinib, according to proposed shareholder class actions filed Thursday and Friday.